期刊
CANCER CELL
卷 33, 期 6, 页码 1048-+出版社
CELL PRESS
DOI: 10.1016/j.ccell.2018.05.004
关键词
-
资金
- National Cancer Institute [R01 CA138398, R01 CA163881, R01 CA200539, R01 CA211073, K99CA190910, 4R00CA190910-03]
- Leukemia and Lymphoma Society [6469-15]
- National Cancer Institute's Cancer Center Support Grant [P30CA012197]
The antitumor effector T helper 1 (Th1) and Th17 cells represent two T cell paradigms: short-lived cytolytic Th1 cells and stem cell-like'' memory Th17 cells. We report that Th9 cells represent a third paradigmthey are less-exhausted, fully cytolytic, and hyperproliferative. Only tumor-specific Th9 cells completely eradicated advanced tumors, maintained a mature effector cell signature with cytolytic activity as strong as Th1 cells, and persisted as long as Th17 cells in vivo. Th9 cells displayed a unique Pu. 1-Traf6-NF-kappa B activation-driven hyperproliferative feature, suggesting a persistence mechanism rather than an antiapoptotic strategy. Th9 antitumor efficacy depended on interleukin-9 and upregulated expression of Eomes and Traf6. Thus, tumor-specific Th9 cells are a more effective CD4(+) T cell subset for adoptive cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据